Replies to post #347335 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

No it doesn't.

Anavex 3-71. Simply, it has an even greater therapeutic potential than blarcamesine. It works therapeutically in doses fractional to those of blarcamesine

Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71

ANAVEX®3-71 was well tolerated in all cohorts receiving ANAVEX®3-71 in single doses ranging from 5 mg to 200 mg daily with no serious adverse events (SAEs) and no significant lab abnormalities in any subject. In the study,

ANAVEX®3-71 Phase 1 Top Line Data Conference Call

Confirmed also in Q&A session from 6:50. 5 - 50mg and 50 - 200mg. From 10:00 Missling knows very little about A3-71 compared to A2-73. The dose range is much broader with A3-71 up to 200mg vs. 60mg with A2-73

Not even 1 magnitude more than A2-73, if anyone knows what that means.

[georgejjl]

falconer66a, I agree 100%.

After Blarcamesine, Anavex 3-71 Will Be Big(ger)

Understandably, the focus on Anavex Life Sciences Corp is centered on Anavex 2-73, blarcamesine; presently in three definitive clinical trials, for Rett syndrome, Parkinson's disease dementia (PDD), and Alzheimer's. The immediate future of Anavex depends on the clinical safety and efficacy of blarcamesine to treat at least one of these otherwise recalcitrant central nervous system (CNS) diseases. A large body of previous postings indicate the evidence why the drug is so very likely to exhibit favorable clinical outcomes.

But presently very little attention is being paid to Anavex's other new drug candidate, Anavex 3-71. I'm not going to re-post any of them, but feel free to do a postings search on Anavex 3-71. Simply, it has an even greater therapeutic potential than blarcamesine. It works therapeutically in doses fractional to those of blarcamesine; with phenomenal therapeutic outcomes against a wider diversity of CNS and other disease categories.

With Rett syndrome results soon to appear for blarcamesine, it will be the headline drug from Anavex; then even more so with the PDD results. Finally, sometime in 2024 will be the big Alzheimer's results.

But watch. waiting actively in the wings is Anavex 3-71, waiting to take the CNS (and perhaps COVID-19) treatment stage, when that act opens next year. Anavex 3-71 may end up being Anavex's biggest drug and revenue generator. Time (and clinical results) will tell. The preclinical data from murines (lab rodents), like those previously from blarcamesine, are extremely favorable; against a much wider body of diseases; particularly by muscarinic receptor activation.

Good luck and GOD bless,

[plexrec]

" sometime in 2024 will be the big Alzheimer's results."--2 more years ??? With readout for current AD trial to come later this year-would surely expect something very positive on AD at an earlier date !!!! perhaps down under the TDA makes a big move !!!!!

[frrol]

"It works therapeutically in doses fractional to those of blarcamesine; with phenomenal therapeutic outcomes against a wider diversity of CNS and other disease categories." No, and that isn't 'science'.